Back Bay Life Science Report

Jonathan P. Gertler and Peter Bak
  • 4,0 (4)
  • MÉDECINE
  • DEUX FOIS PAR SEMAINE
Back Bay Life Science Report

Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, strategic, and financial analysis at the intersection of science and business.

  1. 08/11/2024

    The Optimism of Bispecific Antibodies

    The topic of bispecific antibodies has been an area of interest in the pharma space for a long time now. The recent news of the notable late-stage data from Akeso and Summit’s PD-1/VEGF bispecific antibody ivonescimab to treat non-small cell lung cancer that has captured the industry writ large encouraged us to revisit the topic. To date, there have been ten bispecific antibody approvals in oncology, seven of which are for hematological malignancies. Recently, there has been more traction in development pipelines for solid tumors. Most bispecific antibody approvals are currently or projected to be above the $1M annual revenue threshold. Podcast topics include:  • The biologics of a bispecific antibody • The benefits of a bispecific antibody compared to autologous therapies • The buzz around Akeso and Summit’s PD-1 VEGF bispecific antibody asset • The broad state of bispecifics in approved products and development pipelines • The potential of trispecifics, bispecific conjugates and beyond

    27 min
  2. Dynamics in Healthcare Focused Markets

    30/09/2024

    Dynamics in Healthcare Focused Markets

    In this DNB//Back Bay Healthcare Capital Markets Episode, Vasilios Kofitsas, Partner and Managing Director at Back Bay Life Science Advisors speaks with Jim Cirenza and Kristoffer Braaten of DNB Bank in New York. They focus on key drivers affecting markets this year and discuss the recent news of the Fed’s decision to cut interest rates by 50-basis points.  Topics in the podcast include:  After two difficult years, the appearance of a healthy market rotation since July The Fed’s decision mid-September to cut rates by 50 basis points Healthcare IPOs: historical and recent activity – is the window opening?An outlook including headwinds and tailwinds that may impact the healthcare sectorWe welcome listener questions and/or topics you’d like to learn more about. You can listen to previous episodes here or submit your inquiries here. Learn more about the DNB//Back Bay Partnership and read our disclaimers at https://www.bblsa.com/dnb-back-bay-partnership.

    21 min

  3. 16/09/2024

    From NASH to MASH: Current Market Dynamics in Hepatology

    After a summer away from podcasting, Back Bay Life Science Advisors’ Dr. Pete Bak and Christian Thienel are back on the mic to discuss current market dynamics in liver disease with a focus on one of the most closely watched space in hepatology, MASH.  The big news includes a rebrand from NASH (non-alcohol related steatohepatitis) to MASH (metabolic dysfunction-associated steatohepatitis), the FDA approval of Madrigal Pharmaceutical’s Rezdiffra and real-time court rulings in Europe that may affect the rate of play for Ocaliva, a drug used to treat adults with primary biliary cholangitis here in the US. As Christian mentions in this episode, “The path to success is not always a straight line.” Other topics in this podcast include:  Hepatology market dynamics over the past five years, including activity from Gilead, Novo Nordisk, Intercept and CymaBay How treatment for primary biliary cholangitis, an autoimmune condition, went from a one to a three-product market Payer monographs and what’s required for hepatology drugsThe EMA recommendation earlier this month to revoke Ocaliva’s marketing authorization Which companies are active in the rare liver disease space and how they differentiate themselves Thank you for listening. You can find previous episodes of the podcast here.   We’d love to hear from you. Ask questions and submit your feedback.

    28 min
  4. Key Considerations for a US Healthcare IPO

    22/05/2024

    Key Considerations for a US Healthcare IPO

    In this DNB//Back Bay Healthcare Capital Markets podcast episode, learn about the key considerations, mechanics and timelines of going public on a US exchange.    Topics in this podcast include:    An overview of the decision-making process through execution for US-based and ex-US healthcare companies thinking about listing in the USCore considerations after deciding to pursue a US listing and how to prepare most effectivelyBuilding the “IPO advisory team”: types of advisors (legal, accounting, banking, IR firms, IP, etc.) and when to bring them inKey documents and associated timelines related to the SEC documentation as well as investor outreachWhat are the “don’ts” or mistakes companies make and how to avoid them  You can listen to previous episodes here or submit your inquiries here.   About our guests:   DNB//Back Bay is a committed partner throughout the healthcare development journey, addressing positioning, partnering, financing, M&A strategies, and listing support and execution on US and Nordic exchanges. Our team of more than 100 healthcare strategy and financial specialists spans the globe. Learn more about the DNB//Back Bay Partnership and read our disclaimers at https://www.bblsa.com/dnb-back-bay-partnership.   Cooley is among the top law firms for healthcare, tech and life science IPOs on both the issuer-side and underwriter-side. Their team of 1,300 lawyers is spread across 19 offices worldwide.

    35 min

  5. 30/04/2024

    Drug Development in Obesity

    Guests: Pete Bak and Christian Thienel   Length: 27 minutes   In this episode of The Life Science Report, Dr. Pete Bak and Back Bay Director, Christian Thienel catch up on the area attracting the most industry interest over the past couple of years: the anti-obesity space.   From big players looking to capitalize on the renewed interest in the obesity space to the staggering success of Novo Nordisk’s and Eli Lilly’s GLP-1 agonists (Ozempic, Wegovy, Mounjaro, and Zepbound) for glycemic control and weight loss, there’s a lot to cover.   Topics in this podcast include: A brief introduction to glucagon-like peptide 1 (GLP-1) agonistsWhy GLP-1s’ popularity is skyrocketing as treatment for type 2 diabetes and obesityHow amylin and petrelintide (a long-acting amylin analogue) are being newly re-imagined for the obesity space, as well as muscle-targeted approaches like myostatin and activinsWhere BD and investor interest lies as these drugs are expected to have north of $150B in sales annually within the next decadeWhat’s happening in early to late-stage drug developmentWhat the future holds for this sector, possibly to include cannabinoid one receptor inverse agonists and mitochondrial targets for metabolic disease  As always, thank you for joining us. Did you know we welcome listener questions? If there any areas you’d like us to explore further in metabolic disease and obesity, please let us know. Submit your questions here. Our Nordic-American Healthcare Conference 2025 will feature metabolic track. Learn more: https://nordicamericanhealthcareconference.com/   You can find previous episodes of the podcast here.

    27 min
  6. The Current Dynamics in Capital Markets

    15/04/2024

    The Current Dynamics in Capital Markets

    Welcome to another episode with the DNB//Back Bay Partnership for Healthcare. In this episode Jonathan Gertler, Back Bay CEO and Managing Partner, is once again joined by James Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director of US Equity Capital Markets at DNB, and Vasilios Kofitsas, Managing Director of Investment Banking at Back Bay Life Science Advisors, to talk about current market dynamics and the 2024 IPO outlook in the US and in Europe. Topics in this podcast include: Trends, cycles and the current state of capital markets in Europe and the USIPO performance for Q1 2024 vs. previous yearsTop characteristics of companies well-suited to go public and be successfulIPO market dynamics in Europe vs. the USExpectations and advice for companies contemplating going publicAs always we welcome listener questions and/or topics you’d like to learn more about. You can listen to previous episodes here or submit your inquiries to info@bblsa.com. Learn more about the DNB//Back Bay Partnership and read our disclaimers at https://www.bblsa.com/dnb-back-bay-partnership.

    22 min

  7. 18/03/2024

    Vaccine Developments 2024: A Podcast Discussion on Latest Vaccine Technology and Ongoing Clinical Developments

    Guests: Pete Bak and Christian Thienel   Length: 37 minutes   With the advent of COVID-19 in 2020 and 2021, we saw a tremendous amount of interest in not only COVID vaccines, but other companies riding the tailwind and developing vaccine therapies that span across viral illness, maternal infections and bacterial infections.   In this episode resident immunologist Dr. Pete Bak and Christian Thienel discuss vaccine technology, up-and-coming areas of interest, such as RSV, and the vaccines currently in late-stage clinical development.   Topics in this podcast include:   Vaccine technology, vaccine types and their varying levels of durabilityThe ongoing interest of vaccine development for RSV, including data from GSK’s Arexvy and Pfizer’s Abrysvo vaccinesHow recommendations from the Advisory Committee on Immunization Practices (ACIP) influence commercial dynamicsThe interesting chess game of scheduling vaccines as they relate to COVID, flu and RSV (seasonality versus strains and antigens) Vaccine development and data as it applies to Cytomegalovirus (CMV) and Epstein-Barr (EBV)News from the bacterial front: MinervaX leading the way with a maternal vaccine against Group B streptococcus infections with a very large series B round for $54M; Pfizer’s recent Prevnar 20 against pneumococcal pneumoniaPricing, reimbursement and the interplay with ACIP guidelines  As always, we welcome listener questions and/or topics you’d like to learn more about.   You can listen to previous episodes here or submit your inquiries here.

    38 min

  8. 14/02/2024

    Trends and Investment Activity in Radiopharmaceuticals and Psychedelics

    A Podcast Discussion on the Trends and Investment Activity in Radiopharmaceuticals and Psychedelics Guests: Pete Bak and Christian ThienelLength: 25 minutes Here at Back Bay we’ve seen a number of notable trends in the radiopharmaceutical and psychedelic spaces playing out over the past couple of years. Increasingly, investors have been asking our opinions and perspectives on these topics. Our team has written these whitepapers to address industry interest: The Radiopharmaceutical Renaissance: Radiating Hope in MedicineVision of Commercial Success: Investment and Partnering Landscape for Psychedelics In this episode, Dr. Pete Bak and Christian Thienel talk through the uptick of activity in these focus areas and discuss where the future of radiopharmaceuticals and psychedelics might be heading. Topics in this podcast include: A brief introduction into the history of radiation and radiopharmaWhy the early promise of first-generation radiopharmaceuticals like Zevalin and Bexxar didn’t turn out to be as commercially successfulKey advancements in manufacturing and production for second-generation products like Xofigo, Lutathera and PluvictoThe “theranostic” (therapeutic and diagnostic) potential of radiopharmaceuticalsThe growing investment and R&D support for psychedelics from private companies and academics, especially with the Otsuka and Mindset acquisition for $80M in 2023Realities within the new paradigm of novel treatments and patient/provider protocols adhering to the FDA’s Risk Evaluation and Mitigation StrategyThe evolving nature of the antibacterial space and some notable financing deals, three within two months (Antabio, Clarimedix and Revagenix)Listen to the full episode here.

    26 min
Tout afficher (31)

Notes et avis

4
sur 5
4 notes

À propos

Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, strategic, and financial analysis at the intersection of science and business.

Informations

  • Création
    Jonathan P. Gertler and Peter Bak
  • Années d’activité
    2021 - 2024
  • Épisodes
    31
  • Classification
    Tous publics
  • Copyright
    © 2021 Back Bay Life Science Advisors
  • Site web de l’émission
    Back Bay Life Science Report

Vous aimeriez peut‑être aussi

Pour écouter des épisodes au contenu explicite, connectez‑vous.

Recevez les dernières actualités sur cette émission

Connectez‑vous ou inscrivez‑vous pour suivre des émissions, enregistrer des épisodes et recevoir les dernières actualités.
Choisissez un pays ou une région

Afrique, Moyen‑Orient et Inde

Asie‑Pacifique

Europe

Amérique latine et Caraïbes

États‑Unis et Canada